200 related articles for article (PubMed ID: 33535033)
1. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.
Carrot-Zhang J; Yao X; Devarakonda S; Deshpande A; Damrauer JS; Silva TC; Wong CK; Choi HY; Felau I; Robertson AG; Castro MAA; Bao L; Rheinbay E; Liu EM; Trieu T; Haan D; Yau C; Hinoue T; Liu Y; Shapira O; Kumar K; Mungall KL; Zhang H; Lee JJ; Berger A; Gao GF; Zhitomirsky B; Liang WW; Zhou M; Moorthi S; Berger AH; Collisson EA; Zody MC; Ding L; Cherniack AD; Getz G; Elemento O; Benz CC; Stuart J; Zenklusen JC; Beroukhim R; Chang JC; Campbell JD; Hayes DN; Yang L; Laird PW; Weinstein JN; Kwiatkowski DJ; Tsao MS; Travis WD; Khurana E; Berman BP; Hoadley KA; Robine N; ; Meyerson M; Govindan R; Imielinski M
Cell Rep; 2021 Feb; 34(5):108707. PubMed ID: 33535033
[TBL] [Abstract][Full Text] [Related]
2. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
5. Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development.
Mickler EA; Zhou H; Phang TL; Geraci MW; Stearman RS; Sears CR
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769463
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
7. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
8. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Oncogenic
Cai D; Choi PS; Gelbard M; Meyerson M
Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
[TBL] [Abstract][Full Text] [Related]
11. STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
Dziadziuszko R
J Thorac Oncol; 2022 Mar; 17(3):351-352. PubMed ID: 35216730
[No Abstract] [Full Text] [Related]
12. Identifying metabolic reprogramming phenotypes with glycolysis-lipid metabolism discoordination and intercellular communication for lung adenocarcinoma metastasis.
Li X; Tang L; Deng J; Qi X; Zhang J; Qi H; Li M; Liu Y; Zhao W; Gu Y; Qi L; Li X
Commun Biol; 2022 Mar; 5(1):198. PubMed ID: 35301413
[TBL] [Abstract][Full Text] [Related]
13. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
[No Abstract] [Full Text] [Related]
15. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
16. NRF2-Driven
Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L
Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982
[TBL] [Abstract][Full Text] [Related]
17. Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples.
Li J; Zhang C; Zhang C; Wang H
Aging (Albany NY); 2020 May; 12(10):9868-9881. PubMed ID: 32445554
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
[TBL] [Abstract][Full Text] [Related]
19. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
20. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
